Abrocitinib resulted in a recaptured response for a large proportion of patients with atopic dermatitis suffering from flares.<\/p>\n
A team, led by Jonathan Silverberg, George Washington University, evaluated the efficacy of abrocitinib as a rescue therapy in data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) 2022.<\/p>\n
In the JADE REGIMEN trial, investigators examined the efficacy of abrocitinib-induced responses with continual, reduced dose, or withdrawal of the treatment in patients with moderate-to-severe atopic dermatitis.<\/p>\n
The investigators selected a patient population who flared during the maintenance period to receive abrocitinib rescue treatment.<\/p>\n
Responders to abrocitinib 200 mg, defined by the Investigators Global Assessment (IGA) 0\/1 with at least a 2 grade improvement and 75% improvement in Eczema Area and Severity Index (EASI-75), were randomly assigned to either abrocitinib 200 mg, abrocitinib 100 mg, or placebo for 40 weeks.<\/p>\n
Patients who flared during the maintenance period, defined as at least a 50% loss of week-12 EASI response and at least 2 IGA grades, were offered rescue therapy of abrocitinib 200 mg and topical corticosteroids or calcineurin inhibitors for 12 additional weeks.<\/p>\n
The investigators evaluated responses defined as recaptured IGA, EASI, or Peak Pruritus Numerical Rating Scale (PP-NRS) as scores not worse than randomization baseline responses.<\/p>\n
The investigators enrolled 16.2% (n = 43) of the abrocitinib 200 mg cohort, 39.2% (n = 104) of the abrocitinib 100 mg group, and 76.4% (n = 204) of the placebo arm into the rescue study following protocol-defined flares.<\/p>\n
The results show at week 12 the proportion of patients recapturing IGA response was 35.7% (95% CI, 21.2-50.2%), 50.5% (95% CI, 40.8-60.1%), and 74.0% (95% CI, 67.8-80.1%), respectively.<\/p>\n
For EASI response, it was 33.3% (95% CI, 19.1-47.6%), 32.0% (95% CI, 23.0-41.1%), and 57.1% (95% CI, 50.2-64.1%) and for PP-NRS response it was 28.6% (95% CI, 9.2-47.9%), 39.7% (95% CI, 27.1-52.2%), and 68.2% (95% CI, 58.5-77.9%) for the abrocitinib 200 mg, 100 mg, and placebo arms, respectively.<\/p>\n
Rescue therapy with abrocitinib 200 mg plus topical medicated therapy recaptured response in patients who flared during the maintenance period of JADE REGIMEN, the authors wrote.<\/p>\n
The study, Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN, was published online by the Journal of Allergy and Clinical Immunology.<\/p>\n
<\/p>\n
Read the original post: Abrocitinib resulted in a recaptured response for a large proportion of patients with atopic dermatitis suffering from flares. A team, led by Jonathan Silverberg, George Washington University, evaluated the efficacy of abrocitinib as a rescue therapy in data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) 2022 Continue reading
\nAbrocitinib Working as a Rescue Therapy for Atopic Dermatitis - MD Magazine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"